We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+8.97%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.76B
AUM Growth
-$24.8M
Cap. Flow
-$295M
Cap. Flow %
-10.7%
Top 10 Hldgs %
47.94%
Holding
172
New
14
Increased
31
Reduced
25
Closed
39

Top Buys

Rank Stock Value
1
AGN
Allergan plc
AGN
+$27.4M
2
SHPG
Shire pic
SHPG
+$25.4M
3
ILMN icon
Illumina
ILMN
+$22.1M
4
MDVN
MEDIVATION, INC.
MDVN
+$19.9M
5
HCA icon
HCA Healthcare
HCA
+$14.3M

Top Sells

Rank Stock Value
1
VTRS icon
Viatris
VTRS
+$72.3M
2
ALKS icon
Alkermes
ALKS
+$45.9M
3
AET
Aetna Inc
AET
+$36.3M
4
MDRX
Veradigm Inc. Common Stock
MDRX
+$23M
5
AKRX
Akorn Inc
AKRX
+$22M

Sector Composition

Rank Sector Weight
1 Healthcare 88.47%
2 Real Estate 3.59%
3 Financials 0%
4 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RMR icon
126
The RMR Group
RMR
$333M
$107K ﹤0.01%
+7,441
New +$105K
LRMR icon
127
Larimar Therapeutics
LRMR
$398M
$84K ﹤0.01%
1,109
– –
ABBV icon
128
AbbVie
ABBV
$455B
$9K ﹤0.01%
156
-164,000
-100% -$9.45M
ALKS icon
129
CALL
Alkermes
ALKS
$8.39B
– –
-163,200
Closed -$9.57M
ALNY icon
130
CALL
Alnylam Pharmaceuticals
ALNY
$27.4B
– –
-29,500
Closed -$2.37M
BLUE
131
CALL
DELISTED
bluebird bio
BLUE
– –
-5,203
Closed -$5.77M
BMRN icon
132
CALL
BioMarin Pharmaceuticals
BMRN
$11.7B
– –
-35,500
Closed -$3.74M
BMY icon
133
CALL
Bristol-Myers Squibb
BMY
$132B
– –
-177,200
Closed -$10.5M
CI icon
134
CALL
Cigna
CI
$76.1B
– –
-74,200
Closed -$10M
CI icon
135
Cigna
CI
$76.1B
– –
-74,251
Closed -$10M
CRDF icon
136
Cardiff Oncology
CRDF
$66.2M
– –
-7,639
Closed -$3.13M
ESPR
137
CALL
DELISTED
Esperion Therapeutics
ESPR
– –
-102,800
Closed -$2.42M
HUM icon
138
CALL
Humana
HUM
$44B
– –
-58,900
Closed -$10.5M
INCY icon
139
CALL
Incyte
INCY
$24.9B
– –
-93,700
Closed -$10.3M
IONS icon
140
Ionis Pharmaceuticals
IONS
$8.81B
– –
-147,000
Closed -$5.94M
KPTI icon
141
CALL
Karyopharm Therapeutics
KPTI
$159M
– –
-21,127
Closed -$3.34M
LXRX icon
142
CALL
Lexicon Pharmaceuticals
LXRX
$1.04B
– –
-353,900
Closed -$3.8M
MDT icon
143
CALL
Medtronic
MDT
$110B
– –
-82,700
Closed -$5.54M
MGNX icon
144
MacroGenics
MGNX
$240M
– –
-12,743
Closed -$273K
MPT
145
CALL
Medical Properties Trust
MPT
$2.81B
– –
-70,300
Closed -$2.67M
PBYI icon
146
CALL
Puma Biotechnology
PBYI
$402M
– –
-45,400
Closed -$3.42M
QURE icon
147
CALL
uniQure
QURE
$2.93B
– –
-102,800
Closed -$2.1M
SAGE
148
CALL
DELISTED
Sage Therapeutics
SAGE
– –
-82,800
Closed -$3.5M
UNH icon
149
CALL
UnitedHealth
UNH
$383B
– –
-89,700
Closed -$10.4M
VSTM icon
150
Verastem
VSTM
$536M
– –
-41,667
Closed -$895K
3 4 5
6
7

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q4 2015 Portfolio in Review

As of Q4 2015, Tekla Capital Management held 172 positions worth $2.76B, down 0.89% from $2.78B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Tekla Capital Management withdrew a net $295M in Q4 2015, closing 39 positions and reducing 25 holdings. Its most notable exit was Aetna Inc, an estimated $36.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 81% a quarter earlier, followed by Real Estate and Financials.

Against the trend, Tekla Capital Management opened a new position in Sanofi worth $13M.

  • Tekla Capital Management's largest Q4 2015 buy was Sanofi: 305,000 shares worth $13M.
  • Tekla Capital Management added most to Allergan plc in Q4 2015, an estimated $27.4M increase.
  • Tekla Capital Management's biggest Q4 2015 reduction was Viatris, cutting an estimated $72.3M.
  • Tekla Capital Management fully exited Aetna Inc in Q4 2015, selling an estimated $36.3M.
  • Tekla Capital Management's ten largest holdings make up 48% of its $2.76B portfolio in Q4 2015.
  • Tekla Capital Management opened 14 new positions and closed 39 in Q4 2015.
  • Tekla Capital Management's portfolio value fell 0.89% quarter-over-quarter to $2.76B.

Based on Tekla Capital Management's 13F filing for Q4 2015, filed 9 Feb 2016.